RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10612097
SERIAL NO

15682062

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed herein is a method of using erythroid expression levels of RNF41 as a predictive biomarker for responsiveness to lenalidomide (LEN) in patients with non-del(5q) MDS.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC12902 MAGNOLIA DRIVE TAMPA FL 33612-9497

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
List, Alan Tampa, US 19 13

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 7, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 7, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00